Josep Llovet
Robert Mayer
Sorafenib The ‘New Standard’ for Advanced Liver Cancer
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
Sorafenib could become the very first standard first-line systemic treatment to be recommended for patients with advanced liver cancer, according to conclusions from phase III study data unveiled at ASCO. Derek Thorne got more on this randomized trial from Josep Llovet, of the IDIBAPS Hospital Clinic in Barcelona, and the Mount Sinai School of Medicine in New York, while Robert Mayer, of the Dana-Farber Cancer Institute in Boston, provided comment.
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
Sorafenib could become the very first standard first-line systemic treatment to be recommended for patients with advanced liver cancer, according to conclusions from phase III study data unveiled at ASCO. Derek Thorne got more on this randomized trial from Josep Llovet, of the IDIBAPS Hospital Clinic in Barcelona, and the Mount Sinai School of Medicine in New York, while Robert Mayer, of the Dana-Farber Cancer Institute in Boston, provided comment.
Eric Van Cutsem
William Blackstock
First Line Cetuximab Added to FOLFIRI Prolongs Progression Free Survival in Patients with Metastatic Colorectal Cancer
REFERENCE: ABSTRACT 4000, ASCO Annual Meeting Chicago June 1-5, 2007
ERIC VAN CUTSEM, University Hospital Gasthuisberg, Leuven, Belgium
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
A new first-line option for patients with metastatic colorectal cancer prolongs progression free survival. Phase III results from the CRYSTAL trial were presented to the ASCO meeting in Chicago and show that cetuximab in combination with FOLFIRI can reduce the risk of progression by 15 per cent. Eric Van Cutsem told Sarah Maxwell more. William Blackstock added his thoughts about the clinical implications.
ERIC VAN CUTSEM, University Hospital Gasthuisberg, Leuven, Belgium
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
A new first-line option for patients with metastatic colorectal cancer prolongs progression free survival. Phase III results from the CRYSTAL trial were presented to the ASCO meeting in Chicago and show that cetuximab in combination with FOLFIRI can reduce the risk of progression by 15 per cent. Eric Van Cutsem told Sarah Maxwell more. William Blackstock added his thoughts about the clinical implications.
Bernard Nordlinger
William Blackstock
Chemotherapy with Surgery Provides Benefit for Patients with Colorectal Cancer Liver Metastases
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
BERNARD NORDLINGER, Hôpital Ambroise Paré, Paris
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
Patients with colorectal cancer patients who have resectable liver metastases could benefit from chemotherapy before and after their surgery. That’s according to a study presented in Chicago by Bernard Nordlinger of the Hôpital Ambroise Paré in Paris. Derek Thorne talked to him about the trial’s results, and how these could affect clinical practice.
BERNARD NORDLINGER, Hôpital Ambroise Paré, Paris
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
Patients with colorectal cancer patients who have resectable liver metastases could benefit from chemotherapy before and after their surgery. That’s according to a study presented in Chicago by Bernard Nordlinger of the Hôpital Ambroise Paré in Paris. Derek Thorne talked to him about the trial’s results, and how these could affect clinical practice.
Vincent Rajkumar
Low Dose Dexamethasone with Lenalidomide Gives Benefit to Patients with Multiple Myeloma
REFERENCE: ABSTRACT LBA 8025, ASCO Annual Meeting Chicago June 1-5, 2007
Vincent Rajkumar, Mayo Clinic, Minnesota
A study in newly diagnosed myeloma, which compared lenalidomide plus high- or low-dose dexamethasone, has shown that the lower dose gives a better outcome. Vincent Rajkumar of the Mayo Clinic in Minnesota discussed his study with Sarah Maxwell.
Vincent Rajkumar, Mayo Clinic, Minnesota
A study in newly diagnosed myeloma, which compared lenalidomide plus high- or low-dose dexamethasone, has shown that the lower dose gives a better outcome. Vincent Rajkumar of the Mayo Clinic in Minnesota discussed his study with Sarah Maxwell.
Sandra Horning
Maintenance Rituximab Improves Outcomes After CHOP in Large B-Cell Lymphoma
REFERENCE: ABSTRACT 8011, ASCO Annual Meeting Chicago June 1-5, 2007
Sandra Horning, Stanford University, California
Maintenance rituximab after CHOP chemotherapy has been shown to extend time to treatment failure in older patients with diffuse large B-cell lymphoma. This finding is from an intergroup update that looked at 350 patients and compared maintenance rituximab to observation after R-CHOP or CHOP. Co-author Sandra Horning from Stanford University Medical Center spoke with Sarah Maxwell at the ASCO meeting in Chicago.
Sandra Horning, Stanford University, California
Maintenance rituximab after CHOP chemotherapy has been shown to extend time to treatment failure in older patients with diffuse large B-cell lymphoma. This finding is from an intergroup update that looked at 350 patients and compared maintenance rituximab to observation after R-CHOP or CHOP. Co-author Sandra Horning from Stanford University Medical Center spoke with Sarah Maxwell at the ASCO meeting in Chicago.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.
